Upcoming Events More events are coming soon. Past Events 01/12/2023 1:30 PM EST 41st Annual J.P. Morgan Healthcare Conference 01/09/2023 8:45 AM EST Voyager Therapeutics Strategic Collaboration Announcement Conference Call 11/08/2022 8:30 AM EST Q3 2022 Voyager Therapeutics, Inc. Earnings Conference Call 10/04/2022 3:45 PM EDT Chardan’s 6th Annual Genetic Medicines Conference 09/14/2022 9:40 AM EDT Baird's 2022 Global Healthcare Conference 09/07/2022 3:10 PM EDT Wells Fargo 2022 Healthcare Conference 08/04/2022 4:30 PM EDT Q2 2022 Voyager Therapeutics, Inc. Earnings Conference Call 03/09/2022 12:50 PM EST Cowen 42nd Annual Health Care Conference Corporate Presentation Voyager Therapeutics Corporate Presentation Scientific Presentations Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with Enhanced Brain Tropism in Non-Human Primates and Mice (ESGCT 2022) Dose-response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-human Primates (ESGCT 2022) Evaluation of an Early, Late, Very Late Expressed Rep in a Recombinant Baculovirus to Produce a More Potent AAV-based Gene Therapeutic in Insect Cells (ESGCT 2022) Identification and Characterization of Novel Anti-tau Antibodies that Inhibit Tau-seed Mediated Pathology in a P301S Tauopathy Mouse Model of Alzheimer’s Disease and Tauopathies (AAIC 2022) Efficacy of a Novel Vectorized Antibody Targeting the C-terminal Domain of Tau, Using Systemic Dosing of a Blood Brain Barrier Penetrant AAV Capsid in Mouse Models of Tauopathies (AAIC 2022)
Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with Enhanced Brain Tropism in Non-Human Primates and Mice (ESGCT 2022)
Dose-response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-human Primates (ESGCT 2022)
Evaluation of an Early, Late, Very Late Expressed Rep in a Recombinant Baculovirus to Produce a More Potent AAV-based Gene Therapeutic in Insect Cells (ESGCT 2022)
Identification and Characterization of Novel Anti-tau Antibodies that Inhibit Tau-seed Mediated Pathology in a P301S Tauopathy Mouse Model of Alzheimer’s Disease and Tauopathies (AAIC 2022)
Efficacy of a Novel Vectorized Antibody Targeting the C-terminal Domain of Tau, Using Systemic Dosing of a Blood Brain Barrier Penetrant AAV Capsid in Mouse Models of Tauopathies (AAIC 2022)
